High correlations between primary tumours and locoregional metastatic lymph nodes in non-small-cell lung cancer with respect to glucose transporter type 1-mediated 2-deoxy-2-F18- fluoro-D-glucose uptake
Main Article Content
Abstract
SUMMARY
The purpose of the study was to investigate whether glucose transporter type 1 (Glut-1) mediated 2-deoxy-2-F18- fluoro-D-glucose (FDG) uptake of primary tumour is related to the likelihood of malignancy involvement in loco-regional lymph nodes (LNs) in 126 non-small-cell lung cancer (NSCLC) patients (M:F = 103:23, age = 65 ± 9.7 years). Maximum standardized uptake values (maxSUV) and Glut-1 expression levels (determined by PET and immunostaining, respectively) of primary tumours and PET positive loco-regional LNs were compared.
Significant correlations were found between malignant LNs and primary tumours with respect to maxSUV (r = 0.6451, p < 0.0001), %Glut-1 expression (r = 0.8341, p < 0.0001) and Glut-1 staining intensity (p = 0.827, p < 0.0001). The areaunder- curve value for LN differentiation using lymph node maxSUV was significantly higher in patients with a primary tumour maxSUV of >6 (AUC = 0.775, p = 0.0001).
High correlations between the primary tumours and metastatic LNs in NSCLC with respect to the Glut-1 mediated FDG uptake may be useful for mediastinal LN discrimination by FDG-PET.
Article Details
Keywords
Non-small-cell lung cancer, FDG-PET, Lymph node, Glucose transporter
References
1. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group. Chest 1997;112 :1480–6.
2. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348 :2500–7.
3. Higashi K, Ueda Y, Sakurai A, et al. Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med 2000;27 :1778–85.
4. Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 2004; 25:11–7.
5. Mamede M, Hig ashi T, Kitaichi M, et al. [18F]FDG uptake and PCNA, Glut-1, and hexokinase-II expressions in cancer s and inflammatory lesions of the lung. Neoplasia 2005; 7:369–79.
6. Higashi K, Ueda Y, Ayabe K, et al. FD G PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with his topatholog ical features. Nucl Med Commun 2000; 21:707–14.
7. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deox y-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999; 17:3201–6.
8. Higashi K, Ueda Y, Arisaka Y, et al. 18F- FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002; 43:39–45.
9. Jeong HJ, Min JJ, Park JM, et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002;23 :865–70.
10. Sasaki R, Komaki R, Macapinlac H, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005;23 :1136–43.
11. Nguyen XC, Lee WW, Chung JH, et al. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 2007; 62:214–9.
12. Higashi K, Ito K, Hiramatsu Y, et al. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. J Nucl Med 2005; 46:267–73.
13. Cerfolio RJ, Bryant AS. Ratio of the maximum standardized uptake value on FDG-PET of the mediastina l (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with non-small-cell lung cancer. Ann Thorac Surg 2007;83 :1826–9 [discussion 1829-30].
14. Chung JH, Cho KJ, Lee SS, et al. Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging. J Nucl Med 2004; 45 :999–1003.
15. Chung JH, Lee WW, Park SY, et al. FDG uptake and glucose transporter type 1 expression in lymph nodes of non-small cell lung cancer. Eur J Surg Oncol 2006; 32:989–95.
16. Lee WW, Chung JH, Jang SJ, et al. Consideration of serum glucose levels during malignant mediastinal lymph node detection in non-small-cell lung cancer by FDG-PET. J Surg Oncol 2006;94 :607–13.
17. Song YS, Lee WW, Chung JH, Park SY, Kim YK, Kim SE. Correlation between FD G uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer 2008; in press. doi:10.1016/j.lungc an.2007.11.012.
18. Wahl R. Principles of cancer imaging with fluorodeoxyglucose. In: Wahl R, editor. Principles and practice of positron emission tomography. Philadelphia: Lippincott Williams and Wilkins; 2002. p. 100–10.
19. .
20. Mountain CF, Dresler CM. Regional lymph node classifi cation for lung cancer staging. Chest 1997;111 :1718–23.